CSIMarket Company Name, Ticker, Customers, else..
 
Enzymotec Ltd.  (ENZY)
 

Enzymotec Ltd.'s Customers Performance

ENZY


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
ENZY's Source of Revenues

• List of ENZY Customers




for the same period Enzymotec Ltd.

• List of ENZY Customers

Enzymotec Ltd.'s Business Units






Enzymotec Ltd.'s Comment on Sales, Marketing and Customers



We sell our nutrition products to manufacturers of branded products in different markets around the world. For example, we have developed relationships with infant formula manufacturers who partner with us in bringing our ingredients for infant formula to the end-user market. With respect to our other Nutrition products, we target customers that have a significant presence in the vitamin and mineral supplement, or VMS, industry within their geographic markets. In our VAYA Pharma segment, the majority of our products are marketed directly to physicians by our dedicated sales personnel, but we have also partnered with pharmaceutical companies to provide our products outside of the United States, Singapore and Hong Kong.

Nutrition Segment

AL, our Swedish joint venture which is 50% owned by us and 50% owned by AAK, seeks to position InFat as a strategic ingredient that enables its customers to strengthen their premium brands of infant formula.
Sn-2 palmitate has been incorporated in infant formula products by companies such as Danone, Nestlé, Wyeth and Heinz. AL is a major supplier of the sn-2 palmitate in the market. AL also seeks to target additional infant formula manufacturers and brands to incorporate the InFat products into their products.

The other customers in our Nutrition segment include leading VMS manufacturers and retailers. We target customers with well-developed marketing and distribution infrastructure, strong relationships with and knowledge of their end-customers, awareness of global industry trends and scientific expertise in our fields. We are currently seeking to establish strategic relationships with customers that market and sell their products to mass market retailers.

VAYA Pharma Segment

In the United States, Singapore and Hong Kong, the marketing of our VAYA Pharma products are carried out directly by our dedicated sales personnel , and such products are distributed by pharmaceutical wholesalers, by our on-line pharmacy and in some cases by physicians directly to end users. Outside of the United States, Singapore and Hong Kong, where we are not developing our own specialized marketing and sales staff of medical representatives, we seek to partner with leading providers of pharmaceuticals and other health products in specific geographic markets by licensing our VAYA Pharma brands, often on an exclusive basis, in order to leverage our partners’ market presence and distribution capabilities. To date, we have partnered with Teva Pharmaceutical Industries Ltd. in Israel and Atlantis Ilac in Turkey. We do not currently derive material revenues from these arrangements.